Starpharma Holdings Ltd. (OTCMKTS:SPHRY – Get Free Report) shares were up 6.8% during trading on Monday . The company traded as high as $2.4750 and last traded at $2.35. Approximately 2,375 shares traded hands during mid-day trading, an increase of 456% from the average daily volume of 428 shares. The stock had previously closed at $2.20.
Starpharma Stock Performance
The company has a fifty day simple moving average of $2.35 and a two-hundred day simple moving average of $1.41. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.95 and a current ratio of 4.32.
Starpharma Company Profile
Starpharma is a clinical-stage biopharmaceutical company specializing in the development of dendrimer-based products across infectious disease, oncology and ophthalmology. Its proprietary dendrimer platform, DEP™ (Dendrimer Enhanced Products), enables precise molecular engineering to enhance drug delivery, targeting and safety profiles. The company’s lead product, VivaGel®, is a topical microbicide that has been approved in multiple markets for the treatment and prevention of bacterial vaginosis and is in clinical development for antiviral applications.
In addition to VivaGel, Starpharma is advancing pipeline candidates that leverage DEP technology to improve the performance of established and novel therapeutic agents.
Recommended Stories
- Five stocks we like better than Starpharma
- Do not delete, read immediately
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- Can Any Expenses Be Deducted From Capital Gains Tax?
- The Last Gold Bull Market
Receive News & Ratings for Starpharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Starpharma and related companies with MarketBeat.com's FREE daily email newsletter.
